You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 25, 2024

Litigation Details for Heron Therapeutics, Inc. v. Fresenius Kabi USA, LLC (D. Del. 2022)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Heron Therapeutics, Inc. v. Fresenius Kabi USA, LLC
The small molecule drugs covered by the patents cited in this case are ⤷  Sign Up and ⤷  Sign Up .

Details for Heron Therapeutics, Inc. v. Fresenius Kabi USA, LLC (D. Del. 2022)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 External link to document
2024-05-15 150 Order - Memorandum and Order Hatch-Waxman Act patent case involving U.S. Patent Nos. 9,561,229 (“the ’229 patent”) and 9,974,794 (…the 229 patent is GRANTED. (4) Heron's motion for summary judgment of claims 111 of the 794 patent is DENIED… (“the ’794 patent”). Plaintiff Heron Therapeutics, Inc. is the owner of both patents. Heron moves for…all citations to the ’229 patent’s specification also apply to the ’794 patent at the same line and page…administration.” ’229 patent at col. 1, ll. 47–49. The asserted patents contain both composition External link to document
2024-06-23 172 Miscellaneous Relief inter alia, U.S. Patent Nos. 9,561,229 (“the ’229 patent”) and 9,974,794 (“the ’794 patent”) (collectively…with the additional patents asserted in Heron’s Complaint, “Heron’s Asserted Patents”), based on Fresenius… 9, 10, and 21 of the ’229 patent; and claims 9 and 10 of the ’794 patent; NOW THEREFORE, …1-8 and 11-20 of the ’229 patent or claims 1-8 and 11-21 of the ’794 patent. 2. Pursuant…infringes Heron’s Asserted Patents, except for claims 9, 10, and 21 of the ’229 patent, and claims 9 and 10 External link to document
2024-07-01 175 Redacted Document Heron’s U.S. Patent Nos. 9,561,229 (“the ’229 patent”) (JTX-001) and 9,974,794 (“the ’794 patent”) (JTX-007…-007) (collectively, “patents-in-suit”). The inventions of the patents-in-suit paved the way for the …two patents: two claims narrowly directed to the formulation (claims 9 and 10 of the ’229 patent), one…formulation is the subject of the patents-in-suit. Heron’s patented formulation is an emulsion of aprepitant…which was considered by the Patent Office and never became an issued patent or covered any actual products—and External link to document
2024-07-02 176 Redacted Document (“the ’793 patent”), 10,500,208 (“the ’208 patent”), 10,624,850 (“the ’850 patent”), 10,953,018 (“the …asserting two patents in this litigation: United States Patent Nos. 9,561,229 (“the ’229 patent”) and 9,974,794…,974,794 (“the ’794 patent”) (collectively, “the patents-in- suit”). The patents-in-suit are listed in…asserted United States Patent Nos. 9,808,465 (“the ’465 patent”), 9,974,742 (“the ’742 patent”), 9,974,793 (“… This is an action alleging patent infringement arising under the patent laws of the United States, External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.